Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $55.38.
A number of brokerages recently weighed in on CLDX. UBS Group began coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Friday, February 28th. Finally, The Goldman Sachs Group decreased their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd.
View Our Latest Stock Report on CLDX
Institutional Investors Weigh In On Celldex Therapeutics
Celldex Therapeutics Trading Down 0.3 %
Shares of Celldex Therapeutics stock opened at $20.35 on Thursday. The company has a fifty day moving average price of $22.73 and a 200 day moving average price of $27.65. Celldex Therapeutics has a twelve month low of $18.61 and a twelve month high of $47.00. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of -7.92 and a beta of 1.76.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $1.25 million. Analysts forecast that Celldex Therapeutics will post -2.48 earnings per share for the current year.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
See Also
- Five stocks we like better than Celldex Therapeutics
- Stock Sentiment Analysis: How it Works
- Can TikTok Stock Picks Really Make You Rich?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- The “Quality” Rotation: Back to Basics Investing
- How Investors Can Find the Best Cheap Dividend Stocks
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.